Introduction
The emerging CCN-family consists of a number of related proteins including CTGF, Cyr61/CEF and nov (=CCN) that have been isolated in various organisms (see Grotendorst, 1997 ; Oemar and LuÈ scher, 1997 for reviews). Members of the CCN-family are secreted proteins distinguished by their organization in four conserved domains and complete conservation of 38 cysteine residues (Grotendorst, 1997; Oemar and LuÈ scher, 1997) . CTGF-family members have been shown to be involved in the regulation of physiological processes as proliferation, cell migration, cell adhesion, chemotaxis, dierentiation and embryogenesis (Grotendorst, 1997; Oemar and LuÈ scher, 1997; Bradham et al., 1991; Kireeva et al., 1996 Kireeva et al., , 1997 . However, apart from wound healing (Igarashi et al., 1993) , systemic sclerosis (Igarashi et al., 1995) and atherosclerosis (Oemar and LuÈ scher, 1997) very little data is available concerning the role of CTGF in human diseases. For malignant disease the only available data so far concerns human glioma cell lines which appear to show dierential expression of CTGF and nov (Xin et al., 1996) . In addition CTGF has been shown to be expressed, together with TGFb in the ®brous stroma of mammary tumors (Frazier and Grotendorst, 1997) . In the named study CTGF mRNA expression was con®ned to stromal ®broblasts in xenografts of mammary tumors.
CTGF mRNA appears to be speci®cally induced to signi®cant levels in human skin ®broblasts only by TGFb but not by other growth factors as PDGF, EGF or bFGF (Grotendorst, 1997; Igarashi et al., 1993) . In this context Grotendorst and colleagues recently identi®ed a new TGFb responsive element located in the CTGF-promoter . Recombinant CTGF has recently been shown to stimulate type I collagen and ®bronectin production in NRK ®broblasts (Frazier et al., 1996) . CTGF could thus be a downstream eector of TGFb which is a potent stimulator of extracellular matrix production.
In the presented paper CTGF was surprisingly identi®ed as immediate early target gene of EGF/ TGFa in human pancreatic cancer cell lines by suppression hybridization. As mentioned above, CTGF has so far been thought to exert its major biological eect on cells of mesenchymal origin, and in particular ®broblasts.
As both, EGF/TGFa and TGFb have been shown to induce ®brosis in the pancreas (Bockman and Merlino, 1992; Sanvito et al., 1995; Menke et al., 1997) it is feasible to assume that CTGF plays an important role in the development of ®brosis in pancreatic diseases as e.g. in pancreatic cancer and chronic pancreatitis.
The work presented here describes the regulation of CTGF expression in human pancreatic cancer cells and its expression in human pancreatic tissues.
Results

Cloning of CTGF as EGF immediate early target gene by suppression hybridization
Suppression hybridization with cDNA from 1 h EGF-treated Panc-1 cells as tester and untreated Panc-1 cells as driver was done to identify EGF/ TGFa immediate early target genes in pancreatic cancer cells. Ninety-six clones obtained by cloning suppression hybridization products in the pT7blue vector were transfered into microtitre plates and used for PCR-ampli®cation. PCR-products were dotted onto Nylon membranes and hybridized with the suppression hybridization product (1 h EGF treated Panc-1 cells vs untreated Panc-1 cells) and the unsubtracted driver (untreated Panc-1 cells). This hybridization yielded 19 clones showing a strong dierence in signal strength. Sequence analysis revealed that several fragments were homologous to human CTGF (accession N8 HSU14750) and to ®sp 12, the mouse homolog of CTGF (accession N8 M70642). The remaining clones will be reported separately. though less prominent results were obtained for the cell line HPAF but for none of the other ®ve tested cell lines. HGF did not induce signi®cant higher levels of CTGF transcript in any of the studied cell lines. Both, TGFb-and EGF/TGFa-induced CTGF transcription was superinduced by cycloheximide pretreatment (Figure 1e and f). Inhibition of de novo transcription with actinomycin D abolished the EGF/TGFa-induced rise of CTGF transcript levels in pancreatic cancer cells (Figure 1e) .
In parallel to the increase of CTGF transcription treatment of Panc-1 cells with TGFb led to an increase of collagen type I transcripts. In contrast EGF/TGFa treatment did not alter transcription of genes coding for collagen type I (Figure 1c and d Figure 2a ). On average CTGF expression was 59-fold enhanced over normal pancreatic tissue from organ donors and 13-fold enhanced over chronic pancreatitis tissue samples. In chronic pancreatitis transcript levels for CTGF were slightly elevated in 12/15 and moderately elevated in 3/15 studied tissue samples. On average transcript levels were 4.5-fold enhanced over those measured in normal pancreatic tissue. In pancreatic cancer tissues the CTGF transcript levels showed a good correlation to the degree of ®brosis detected in tissue sections of the same patients but no correlation to tumor stage (Table 2) .
CTGF, TGFb and collagen type I expression levels were compared in 13 pancreatic cancer tissues and ten chronic pancreatitis tissues (Figure 2a ,b,c, respectively). Elevated levels of TGFb mRNA were found in ten pancreatic cancer tissues (on average 13-fold over control tissues) and two chronic pancreatitis tissues. As shown in Figure 2 tissues with elevated TGFb transcripts showed a concomittant overexpression of CTGF and collagen type I. However, there was no correlation between the magnitude of CTGF, collagen type I and TGFb expression levels in individual tissues. For example, the tissue with the highest level of TGFb transcripts did not show the highest rate of CTGFoverexpression. Only one pancreatic cancer tissue with elevated CTGF and collagen type I transcript levels did not show overexpression of TGFb. In chronic pancreatitis two tissues with moderately and one tissue with highly elevated collagen type I levels did not show overexpression of CTGF or TGFb ( Figure  2a ,b,c, respectively).
In situ hybridization was done to determine the predominant site of transcription of CTGF in pancreatic cancer tissue samples. The largest amount of CTGF transcripts was found in spindle shaped cells in the stroma surrounding the tumor cells, whereas the tumor cells showed only weak to moderate activity and surrounding acini showed no signals. In Figure 2d a section was chosen for presentation in which both, stromal cells and tumor cells show speci®c label. Additional information concerning the predominant site of in vivo CTGF transcription was obtained in nude mouse experiments ( Figure 3 ). In nude mouse xenografts of SUIT-2 pancreatic cancer cell lines transcript levels for human CTGF were barely detectable, whereas in vitro these cell lines showed moderate to high levels of the human transcript. However, in nude mouse xenograft tumors in which the stroma is of mouse origin ®sp 12, the mouse Cells were treated with or without 10 ng/ml TGFb for 24 h and CTGF and TGFb expression was analysed by Northern blot hybridizations. The arrows indicate cell lines showing at least a twofold induction of CTGF/TGFb transcripts. Expression of DPC4 and TbR II was determined by Northern blot hybridizations. +++ (high), ++ (moderate), + (low), (+) (barely detectable), 7 (no) signal. *Nonsense mutation found by Schutte et al. (1996) I  I  III  III  IV  I  III  IV  III  IV n.a.
n.a.: not available homolog of hCTGF, was moderately to highly expressed.
There was a good correlation between collagen type I transcript levels and the total amount of collagen protein measured in nude mouse xenografts and the CTGF and ®sp12 transcript levels (Figure 3 ). SUIT-2 cell lines are clones derived from one primary tumor that dier in their spontaneous metastatic potential in nude mice. For example, the SUIT-2 clone 007 has been shown to have the highest and the SUIT-2 clone 028 the lowest metastatic potential after subcutaneous injection in nude mice (Taniguchi et al., 1992) . Expression of CTGF and ®sp12 occurred independent of the metastatic potential of these cell lines (Figure 3) . 
Discussion
In the presented paper connective tissue growth factor (CTGF) was identi®ed in an approach aimed at identifying immediate early target genes of the EGF/ TGFa signaling cascade in pancreatic cancer cells by use of suppression hybridization techniques. This was surprising as CTGF has so far been thought to be mainly expressed in cells of mesenchymal origin, in particular in ®broblasts (Grotendorst, 1997; Oemar and LuÈ scher, 1997) . In the ®broblast cells studied to date growth factors as EGF, PDGF and FGF only induce minor, transient increases of CTGF transcripts peaking 1 ± 2 h after addition of growth factors (Grotendorst, 1997; Igarashi et al., 1993) . In human ®broblasts only TGFb was able to induce a signi®cant rise of CTGF transcripts reaching maximal values 4 h after addition of the growth factor. In contrast to other growth factors even a short time (1 h) exposure to TGFb caused prolonged activation of CTGF gene expression for 24 ± 48 h after the addition of TGFb to the cells . Our data show that pancreatic cancer cells as tumor cells of epithelial origin display diering patterns of transcriptional CTGF regulation. EGF and TGFa induce both a signi®cant rise of CTGF transcript levels (up to 15-fold) with a maximum 1 ± 2 h after the start of growth factor treatment in 3/7 pancreatic cancer cell lines. TGFb-treatment increased CTGF transcript levels in Panc-1-cells not earlier than 4 h after the start of treatment, and this elevation was sustained after 24 h of treatment. This eect was only observed for Panc-1 and to a lesser extent for HPAF but not for the ®ve additionally tested pancreatic cancer cell lines (IMIM-PC1, IMIM-PC2, Patu8988t, MiaPaca2 and CA-PAN1). As these ®ve cell lines showed no autoinduction of TGFb we analysed the expression status of DPC4/Smad4 and the TGFb type II receptor, which are assumed to participate in the TGFb signaling pathway (Grau et al., 1997; Baldwin et al., 1996; Schutte et al., 1996) . MiaPaca2, IMIM-PC2 and Patu8988t lack expression of TbR II or DPC4 or both. Furthermore a nonsense mutation in the DPC4 gene has been reported in CAPAN1 cells (Schutte et al., 1996) . DPC4 and TbR II are both expressed in IMIM-PC1, though no autoinduction of TGFb could be demonstrated. This may serve as an indication that this cell line may harbor additional yet undetermined mutations or alterations of the TGFb pathway. Thus, in the same way as described for the inhibitory eects of TGFb on tumor cell proliferation, a defective TGFb signaling pathway may be the reason for the lack of induction of CTGF transcripts in the tested pancreatic tumor cell lines. In contrast a larger number of the tested cell lines produced moderate to high CTGF transcript levels when incubated with 10% FCS (n=13/15 tested) or upon treatment with EGF/TGFa (n=3/7 tested), indicating that a considerable fraction of pancreatic cancer cells indeed have the capacity to transcribe CTGF.
As has been shown for TGFb stimulated ®broblasts (Igarashi et al., 1993; Grotendorst et al., 1996) both, TGFb-and EGF/TGFa-induced CTGF transcription was superinduced by pretreatment with cycloheximide in pancreatic cancer cells. These data indicate that TGFb and EGF/TGFa directly regulate CTGF gene expression via a mechanism that is independent of de novo protein synthesis. The superinduction of early response genes by cycloheximide has been attributed to mRNA stabilization e.g. by inhibition of RNA degrading enzymes. Inhibition of de novo transcription with actinomycin D abolished the EGF/TGFa-induced rise of CTGF transcripts in pancreatic cancer cells which indicates that these growth factors directly regulate CTGF expression on the level of transcription Ryseck et al., 1991) .
Since one of the best documented functions of CTGF is to stimulate synthesis of ECM-components in ®broblasts, we studied the time course of CTGF transcripts and of collagen type I transcripts in pancreatic cancer cells upon treatment with EGF/ TGFa and TGFb. Only treatment with TGFb was accompanied by a parallel induction of collagen I transcription, whereas the early transient increase of CTGF induced by EGF/TGFa did not alter collagen I transcription. It has been speculated that CTGF is a downstream mediator of TGFb actions on the ECM, on the proliferation of ®broblasts and the development of ®brosis (Grotendorst, 1997; Frazier et al., 1996; Grotendorst et al., 1996) . This is of paramount importance for the pathogenesis of pancreatic diseases as e.g. pancreatic cancer and chronic pancreatitis, which are characterized by a strong accumulation of ®brotic tissue. The role of TGFb for the development of pancreatic ®brosis has been well documented in human diseases (Friess et al., 1993 ; Van Laethem et al., 1995) and in animal models of pancreatic ®brosis (Sanvito et al., 1995; Menke et al., 1997) . Our in vitro results suggested that in pancreatic cancer tissues CTGF produced by pancreatic cancer cells may contribute to the development of the desmoplastic reaction. 15/19 human pancreatic cancer tissues were shown to overexpress high levels of CTGF transcripts as compared to both normal pancreas and chronic pancreatitis, a tissue characterized by chronic inflammation and ®brosis. On average CTGF transcript levels in pancreatic cancer tissues (59-fold over controls) were signi®cantly higher than those observed in chronic pancreatitis (4.5-fold over controls). CTGF/®sp12 transcript levels in pancreatic cancer tissues and nude mouse xenografts showed a good correlation to the degree of ®brosis and collagen expression. All tissues showing overexpression of CTGF and collagen type I as well displayed enhanced TGFb transcript levels. However, CTGF and collagen type I transcript levels in pancreatic cancer and chronic pancreatitis tissues were much higher than the ones observed for TGFb. In addition there was no good correlation between the magnitude of the transcript levels of the three genes in individual tissues. This may serve as an indication that in the pancreas other factors, in addition to TGFb, participate in the regulation of CTGF.
In situ hybridization and the nude mouse experiments revealed that in human pancreatic cancer tissues stromal cells are the predominant site of CTGF/®sp12 transcription, whereas the tumor cells appear to contribute only to a lesser extent to CTGF transcription. Although in vitro pancreatic cancer cells produce considerable amounts of CTGF transcripts in vivo they appear to provide only a minor contribution to CTGF transcription. Most likely factors secreted in a paracrine fashion by tumor cells as e.g. TGFb induce CTGF transcription in ®broblasts and may be one of the essential mechanisms required for the induction of the desmoplastic reaction in pancreatic cancer tissues.
We conclude that CTGF expressed in connective tissue cells and to a lesser extent in pancreatic tumor cells may be of paramount importance for the development of the characteristic desmoplastic reaction in pancreatic cancer tissues.
Materials and methods
Tissues and cell lines
Human pancreatic cancer cell lines were obtained from the following suppliers: MiaPaca2 and Panc-1 (European Collection of Animal Cell Cultures, Salisbury, UK), Patu8988s and Patu8988t (HP ElsaÈ sser, Department of Cell Biology, Marburg, Germany), HPAF (RS Metzgar, Durham, North Carolina, USA), IMIM-PC1 and IMIM-PC2 (FX Real, Institute Municipal d'I Á nvestigacio Medica, Barcelona, Spain), CAPAN1 and CAPAN2 (American Type Culture Collection, Rockville, USA), SUIT-2 clones S2-007, S2-013, S2-020, S2-028, VP-10, CP-9 (T Iwamura, Miyazaki Medical College, Miyazaki, Japan, reference 15). Human fetal lung ®broblasts (HFL1) were obtained from the European Collection of Animal Cell Cultures (Salisbury, UK). All pancreatic cancer cell lines were incubated in DMEM (Gibco ± BRL) and 10% fetal calf serum (FCS, Gibco ± BRL).
Human tissue from patients with adenocarcinoma of the pancreas (n=19), from patients with chronic pancreatitis (n=15) and human pancreatic tissue from organ donors (n=10) were provided by the Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary (Dr G Varga), the Department of Pathology of the University of Heidelberg, Germany (Professor MoÈ ller) and the Department of General Surgery of the University of Ulm, Germany. All tissue samples were obtained after approval by the local Ethics Committees.
Cytokine treatment of cell lines
Pancreatic cancer cell lines and the HFL cell line were grown to 70 ± 80% con¯uence in medium containing 10% fetal calf serum (FCS, Gibco ± BRL). After 24 h of incubation in serum free medium cells were treated either with EGF (50 ng/ml, Calbiochem), TGFa (25 ng/ml Peprotech Inc., NJ, USA), TGFb (10 ng/ml, R&D Systems, Wiesbaden-Nordenstedt, Germany), HGF (20 ng/ml, R&D Systems) or with medium only. Cytokine treatment was done for 0.5, 1, 2, 4, 8, 24 h. Treatment with cycloheximide (10 mg/ml, Boehringer Mannheim, Germany) and actinomycin D (2 mg/ml, Sigma) was started after 24 h of serum free incubation, 0.5 h before the addition of the respective growth factor.
Generation of nude mouse xenografts
NMRI-nu-nu nude mice were propagated and maintained in a pathogen-free environment. Six to eight week old nude mice were used to generate xenografts. 2610 6 tumor cells in 0.1 ml DMEM were injected subcutaneously into both anks of the nude mouse. Mice were killed 4 weeks after sc injection of tumor cells and xenografts were shock frozen in liquid nitrogen for RNA extraction or ®xed in 10% neutral buered formaldehyde for histological evaluation.
RNA extraction
RNA from cell lines was extracted using the RNA-Clean TM System (AGS, Heidelberg, Germany). RNA from¯ash frozen pancreatic tissue was extracted by use of a standard guanidinium thiocyanate extraction followed by centrifugation in a cesium chloride gradient (Pharmacia LKB, Freiburg, Germany). Poly(A) + -RNA was selected using Dynabeads 1 (Dynal, Hamburg, Germany) as described by the manufacturer.
Northern blotting and hybridization techniques
Thirty mg of total RNA from cell lines and pancreatic tissues were size fractionated on 1% agarose, 8% formaldehyde denaturing gels and transfered to Hybond N + membranes (Amersham-Buchler, Braunschweig, Germany). DNA probes were labeled by random hexamer priming using 32 P-dCTP as radioactive label and hybridized in a standard formamide containing buer at 428C. Stringent washes were done in 0.26SSC/0.1% SDS at 688C. Exposure to X-ray ®lms was 1 ± 7 days at 7708C. Autoradiographies were analysed with an image analysis system consisting of a laser-scanner (Hewlett-Packard Scanjet 4c/t) and the Optimas 1 -software (Stemmer TM , Puchheim, Germany). A standard curve for optical densities (OD) was extrapolated using an unexposed autoradiography as OD=0 and a light exposed (black) autoradiography as OD=100. A cDNA clone for the mouse homolog of CTGF, ®sp12, was obtained from the Resource Centre/Primary Database of the German Human Genome Project (GHGP), Berlin/Germany (IMAGp 998I221327/IMAGE ID 551901). Additional hybridizations were done with the cDNA probes for human collagen al/I (N8 61322, ATCC, Rockville USA), and TGFb1 (N8 59954, ATCC, Rockville, USA) and rat collagen al/I (Drs JK MaÈ kelaÈ and E Vuorio, University of Turku, Finland) A 250 bp RsaI fragment obtained by suppression hybridization with 100% homology to human CTGF (bases 1160 ± 1410 of the sequence with accession N8 HSU14750) was used as hybridization probe.
Suppression hybridization
Suppression hybridization using MMLV reverse transcribed cDNA from 1 h EGF-treated cells as`tester' and medium-treated cells as`driver' was performed using the PCR-Select TM cDNA subtraction kit following precisely the manufacturers protocol (Clontech, Palo Alto, CA, USA). The subtraction hybridization product was cloned in pT7blue-vector (Novagen, Wiesbaden-Nordenstedt, Germany), transformed into E. coli (DH5a strain), plated on LB-agar plates containing ampicillin and picked into a 96-well microtitre plate. Cloned inserts were PCR-ampli®ed in microtitreplates and PCR-products were dot blotted onto Biodyne A membranes (Pall, Dreieich, Germany). Dot blots were hybridized with labeled probes of the suppression hybridization product and the unsubtracted driver (200 ng each). Probes were generated using random hexamer priming and 33 P-dATP as radioactive label. Prior to hybridization probes were competed with 50 mg COT1-DNA (Gibco ± BRL) and 50 mg placental DNA (Sigma) in 56SSC, 0.1% SDS for 2 h at 658C. Hybridization and washing procedures were as described above.
Sequencing
Cloned suppression hybridization fragments were sequenced with an 373A automated Sequencer (Applied Biosystems, Foster City, CA, USA) using the Prism TM DyeDeoxy Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA).
mRNA in situ hybridization mRNA in situ hybridization was done on sections from four dierent pancreatic cancer samples. The CTGF fragment was subcloned in pBluescript II KS + (Stratagene, Heidelberg, Germany). cRNA probes from the subcloned fragment were generated by run-o transcriptions using T7 or T3 RNA polymerase (Gibco ± BRL), ribonucleotides (Pharmacia) and a 35 S-UTP as radioactive label. Sense probes were used as negative controls. Hybridizations were carried out in 50% formamide, 10% dextrane sulfate, 0.3 M sodiumchloride, 10 mM Tris, 10 mM sodium phosphate pH 6.8, 20 mM dithiotreitol, 0.1% Triton-X-100, 0.1 mg/ml E. coli RNA. Hybridizations were done at 428C for 16 h. Slides were washed twice in 50% formamide, 0.3 M sodiumchloride, 10 mM Tris, 1 mM EDTA at 548C for 60 min. After each washing step slides were washed again in 0.3 M sodiumchloride, 10 mM Tris, 1 mM EDTA at 378C for 15 min, followed by a 30-minincubation in the same buer and 40 mg/ml ribonuclease A at 378C. This was followed by additional washes for 30 min each, once in 0.3 M sodiumchloride, 10 mM Tris, 1 mM EDTA, once in 26SSC and once in 0.16SSC. Dehydration was done in ethanol solutions followed by air drying. After covering with photoemulsion (Ilford K5) all slides were exposed at 108C for 4 weeks. Following development sections were stained with giemsa and evaluated by standard light and dark ®eld microscopy. Hybridization signals were scored by two investigators trained in pancreatic cancer histology. For all probes, the signals were evaluated relative to the background signal on control slides hybridized with the sense probe.
Assessment of the degree of ®brosis in pancreatic cancer tissues and nude mouse xenografts
The degree of ®brosis was assessed by two techniques. First a semiquantitative analysis of the degree of ®brosis was done in histological sections of the same pancreatic tissues also used in Northern blot analysis. Fibrosis in tissue sections was scored as: 7=absent, +=weak (530% ®brotic tissue per section), ++=moderate (30 ± 60% ®brotic tissue per section), +++=severe (60 ± 100% ®brotic tissue per section). For a more quantitative analysis the content of total collagen in sections of nude mouse xenografts was determined using a colorimetric method. In brief, deparanized sections from the pancreas were stained in a saturated picric acid solution containing 0.1% fast green FCF (Fluka, Buchs, Switzerland) and Sirius red F3B (Gurr, Poole, UK). The dye which is known to bind speci®cally to collagenous protein (sirius red) and non-collagenous protein (fast green) was eluted from the sections with absolute methanol and 0.1 N NaOH and measured spectrophotometrically at 630 nm and 540 nm respectively. The tissue concentrations of collagen and non-collagenous protein were calculated according to their color equivalent (Lopez- De-Leon and Rojkind, 1985) and expressed as mg collagen/mg total protein in each section.
